Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    15189755 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed Capecitabine as Radiosensitising Agent in Neoadjuvant Treatment of Locally Advanced Resectable Rectal Cancer
Condition: Resectable Rectal Cancer Clinical Stage II and III
Intervention: Drug: Capecitabine

Indicates status has not been verified in more than two years